ClinicalTrials.gg
RecruitingNCT05807321Updated Oct 21, 2025

Fecobionics in Biofeedback Therapy in Dyssynergia Patients

An interventional study of Fecobionics in Dyssynergia and Constipation, sponsored by The California Medical Innovations Institute, Inc.. Recruiting at 2 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by The California Medical Innovations Institute, Inc. · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
21 Years to 75 Years
Sex
All
01

Study summary

Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.

Read the detailed description

This study aims to monitor and predict biofeedback therapy based on mechanism-based and highly integrated data using a new medical device. This study is specifically for patients with dyssynergia before, during, and after biofeedback therapy. The balloon-like Fecobionics device (10 cm long and 1 cm in diameter) will be inserted into the participant's rectum and will record data before and during the expulsion of the device. The participant will be asked to do different motions like cough, squeeze, or push during the procedure. The novel data obtained in this study may help the investigators to identify the patients who will benefit or not benefit from biofeedback therapy before the therapy is done. This will determine the effectiveness of treatments for anorectal disorders.

02

Conditions studied

  • Dyssynergia
  • Constipation

Keywords

  • Fecobionics
  • Biofeedback therapy
  • Defecation
03

In context

Ataxia

149 studies on the registry are indexed under Ataxia; 37 are open to participants now.

This study's planned enrollment of 24 is below the median of 30 across 100 interventional studies indexed under Ataxia.

Browse Ataxia studies →

Lead sponsor

The California Medical Innovations Institute, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must provide written .
  2. Age between 21-75 years.
  3. Subjects must fulfill the criteria for obstructed defecation/dyssynergia and enter the BFT at UCSD or Scripps.

Exclusion criteria

Exclusion Criteria:

  1. Female who is pregnant or lactating.
  2. Prior abdominal or anorectal surgery or bowel resection.
  3. Diagnosis of fecal incontinence, any anorectal symptoms and drug use that affect anorectal function.
  4. Confirmed or suspected COVID-19 infection.
  5. Severe cardiovascular disease.
  6. Subjects not willing to consent and undergo the specified tests in this study.
  7. Other exclusions, that in the opinion of the investigator, the volunteer is not a suitable subject for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Fecobionics

    Device: Fecobionics

Interventions

  • DeviceFecobionics

    Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.

    Also known as: Anorectal manometry, Balloon expulsive test

06

What researchers measure

Primary outcomes

  1. Expulsion Duration

    The time it takes to defecate Fecobionics

    Time frame: 1.5 year

  2. Pressure Difference between front and rear ends of Fecobionics

    A measure of anal sphincter pressure, the driving rectal pressure, and the difference between these two pressures. This is the key to the determination of defecation phases.

    Time frame: 1.5 year

Secondary outcomes

  1. Anorectal angle

    Anorectal angle is an important parameter for defecation

    Time frame: 1.5 year

  2. Mechanical Tension of Fecobionics

    To reflect anorectal function, the mechanical tension will be computed. The tension is equal to anorectal radius multiply pressure.

    Time frame: 1.5 year

  3. Expulsion Velocity

    Measured from the time difference between multiple sensor data

    Time frame: 1.5 year

  4. Cross-sectional area

    Computed by diameter

    Time frame: 1.5 year

07

Study locations

2 of 2 sites recruiting
  • California Medical Innovations Institute
    San Diego, California 92121, United States
    Recruiting
    • Hans Gregersen, PhD · Contacthag@giome.org · 858-249-7400
    • Ghassan Kassab, PhD · Contactgkassab@calmi2.org · 858-249-7400
    • Lucy G Barron Del Solar, MD · Sub investigator
    • Hans Gregersen, MD, PhD · Principal investigator
  • Digestive Health Center- Augusta University
    Augusta, Georgia 30912, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jan 2027, 38 months after the start.

Of 53 non-industry interventional studies with no phase under Ataxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 38 months is above that.

Counting every sponsor, half of 55 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 11, 2023
StartActual
Oct 3, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05807321
Lead sponsor
The California Medical Innovations Institute, Inc.
Collaborators
Scripps Clinic, Augusta University Medical Center
Responsible party
Hans Gregersen, PhD (CEO, The California Medical Innovations Institute, Inc.) — Principal investigator
First posted
Apr 11, 2023
Start date
Oct 3, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 21, 2025

Study contacts

Hans Gregersen, PhD
Contact
hag@giome.org
858-249-7400
Satish Rao, MD, PhD
Contact
srao@augusta.edu
706-7212238

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion